WIN-62005 is used as a selective inhibitor of cyclic AMP phosphodiesterase type III (PDEIII), exhibiting potent inotropic effects in vivo by significantly increasing left ventricular dP/dtmax (LVdP/dtmax) for at least 6 hours after oral administration; it is employed in research to study PDEIII-related cardiovascular functions and mechanisms.